BridgeBio Oncology Therapeutics, Inc. (BBOT) Operating income 2023–2025
BridgeBio Oncology Therapeutics, Inc. (BBOT) annual operating income history from SEC filings — each fiscal year as reported.
-$145.8MFY2025 · since FY2023: -$41,692 → -$145.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$145.8M | -80.3% |
| FY2024 | -$80.9M | -193853.3% |
| FY2023 | -$41,692 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BBOT financial trends
BBOT RevenueBBOT Net incomeBBOT Net marginBBOT Gross profitBBOT Gross marginBBOT Operating marginBBOT Operating cash flowBBOT Free cash flowBBOT Capital expendituresBBOT Return on equityBBOT Stock buybacksBBOT Dividends paidBBOT Total assetsBBOT Total liabilitiesBBOT Shareholders’ equityBBOT overview →